On September 10, Elevance Health rose 3.64% in regular trading, trading at $409.54 per share, with turnover of $185 million. The rally was driven by the company filing with the SEC to reaffirm its full-year earnings guidance, signaling management confidence in second-half operations.

According to the filing, Elevance Health reiterated its fiscal year diluted EPS target of no less than $20.10 and adjusted diluted EPS of no less than $27.00. This guidance was initially raised following a strong second-quarter performance reported in July, when the company posted revenue of $49.83 billion and adjusted EPS of $7.45, exceeding consensus estimates by $1.2 billion and $1.24, respectively. The company also lifted its full-year operating cash flow guidance floor to $6.0 billion at that time.

The reaffirmation comes after an earlier guidance confirmation in June, when the company had set adjusted EPS at a minimum of $26.75. The subsequent upward revision and latest reaffirmation reflect sustained operational momentum across its Health Benefits and Carelon segments within the managed health care industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)